Genomics and proteomics of bone cancer

Aaron G. Marguiles, Vicki Klimberg, Sudeepa Bhattacharrya, Dana Gaddy, Larry J. Suva, Roodman, Berenson, Pearse, Vessella

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Although the control of bone metastasis has been the focus of intensive investigation, relatively little is known about the molecular mechanisms that regulate or predict the process, even though widespread skeletal dissemination is an important step in the progression of many tumors. As a result, understanding the complex interactions contributing to the metastatic behavior of tumor cells is essential for the development of effective therapies. Using a state-of-the-art combination of gene expression profiling and functional annotation of human tumor cells, and surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry of patient serum, we have shown that changes in tumor biochemistry correlate with disease progression and help to define the aggressive tumor phenotype. Based on these approaches, it is apparent that the metastatic phenotype of tumor cells is extremely complex. The identification of the phenotype of tumor cells has benefited greatly from the application of gene expression profiling (microarray analysis). This technology has been used by many investigators to identify changes in gene expression and cytokine and growth factor elaboration (such as interleukin 8). The tumor phenotype(s) presumably also include changes in the cell surface carbohydrate profile (via altered glycosyltransferase expression) and heparan sulfate expression (via increased heparanase activity), to name but a few. These specific alterations in gene expression, identified by functional annotation of accumulated microarray data, have been validated using a variety of approaches. Collectively, the data described here suggest that each of these activities is associated with distinct aspects of the aggressive tumor cell phenotype. Collectively, the data suggest that multiple factors constitute the complex phenotype of metastatic tumor cells. In particular, the differences observed in gene expression profiles and serum protein biomarkers play a critical role in defining the mechanisms responsible for bone-specific colonization and growth of tumors in bone. Future studies will identify the mechanisms that participate in the formation of secondary tumor growths of cancers in bone.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume12
Issue number20 PART 2
DOIs
StatePublished - Oct 15 2006
Externally publishedYes

Fingerprint

Bone Neoplasms
Genomics
Proteomics
Neoplasms
Phenotype
Gene Expression Profiling
Bone and Bones
Gene Expression
Glycosyltransferases
Heparitin Sulfate
Microarray Analysis
Growth
Interleukin-8
Transcriptome
Biochemistry
Disease Progression
Blood Proteins
Mass Spectrometry
Intercellular Signaling Peptides and Proteins
Lasers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Marguiles, A. G., Klimberg, V., Bhattacharrya, S., Gaddy, D., Suva, L. J., Roodman, ... Vessella (2006). Genomics and proteomics of bone cancer. Clinical Cancer Research, 12(20 PART 2). https://doi.org/10.1158/1078-0432.CCR-06-1070

Genomics and proteomics of bone cancer. / Marguiles, Aaron G.; Klimberg, Vicki; Bhattacharrya, Sudeepa; Gaddy, Dana; Suva, Larry J.; Roodman; Berenson; Pearse; Vessella.

In: Clinical Cancer Research, Vol. 12, No. 20 PART 2, 15.10.2006.

Research output: Contribution to journalReview article

Marguiles, AG, Klimberg, V, Bhattacharrya, S, Gaddy, D, Suva, LJ, Roodman, Berenson, Pearse & Vessella 2006, 'Genomics and proteomics of bone cancer', Clinical Cancer Research, vol. 12, no. 20 PART 2. https://doi.org/10.1158/1078-0432.CCR-06-1070
Marguiles AG, Klimberg V, Bhattacharrya S, Gaddy D, Suva LJ, Roodman et al. Genomics and proteomics of bone cancer. Clinical Cancer Research. 2006 Oct 15;12(20 PART 2). https://doi.org/10.1158/1078-0432.CCR-06-1070
Marguiles, Aaron G. ; Klimberg, Vicki ; Bhattacharrya, Sudeepa ; Gaddy, Dana ; Suva, Larry J. ; Roodman ; Berenson ; Pearse ; Vessella. / Genomics and proteomics of bone cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 20 PART 2.
@article{5db1a7973a93468c95802e74e649c111,
title = "Genomics and proteomics of bone cancer",
abstract = "Although the control of bone metastasis has been the focus of intensive investigation, relatively little is known about the molecular mechanisms that regulate or predict the process, even though widespread skeletal dissemination is an important step in the progression of many tumors. As a result, understanding the complex interactions contributing to the metastatic behavior of tumor cells is essential for the development of effective therapies. Using a state-of-the-art combination of gene expression profiling and functional annotation of human tumor cells, and surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry of patient serum, we have shown that changes in tumor biochemistry correlate with disease progression and help to define the aggressive tumor phenotype. Based on these approaches, it is apparent that the metastatic phenotype of tumor cells is extremely complex. The identification of the phenotype of tumor cells has benefited greatly from the application of gene expression profiling (microarray analysis). This technology has been used by many investigators to identify changes in gene expression and cytokine and growth factor elaboration (such as interleukin 8). The tumor phenotype(s) presumably also include changes in the cell surface carbohydrate profile (via altered glycosyltransferase expression) and heparan sulfate expression (via increased heparanase activity), to name but a few. These specific alterations in gene expression, identified by functional annotation of accumulated microarray data, have been validated using a variety of approaches. Collectively, the data described here suggest that each of these activities is associated with distinct aspects of the aggressive tumor cell phenotype. Collectively, the data suggest that multiple factors constitute the complex phenotype of metastatic tumor cells. In particular, the differences observed in gene expression profiles and serum protein biomarkers play a critical role in defining the mechanisms responsible for bone-specific colonization and growth of tumors in bone. Future studies will identify the mechanisms that participate in the formation of secondary tumor growths of cancers in bone.",
author = "Marguiles, {Aaron G.} and Vicki Klimberg and Sudeepa Bhattacharrya and Dana Gaddy and Suva, {Larry J.} and Roodman and Berenson and Pearse and Vessella",
year = "2006",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-06-1070",
language = "English (US)",
volume = "12",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20 PART 2",

}

TY - JOUR

T1 - Genomics and proteomics of bone cancer

AU - Marguiles, Aaron G.

AU - Klimberg, Vicki

AU - Bhattacharrya, Sudeepa

AU - Gaddy, Dana

AU - Suva, Larry J.

AU - Roodman,

AU - Berenson,

AU - Pearse,

AU - Vessella,

PY - 2006/10/15

Y1 - 2006/10/15

N2 - Although the control of bone metastasis has been the focus of intensive investigation, relatively little is known about the molecular mechanisms that regulate or predict the process, even though widespread skeletal dissemination is an important step in the progression of many tumors. As a result, understanding the complex interactions contributing to the metastatic behavior of tumor cells is essential for the development of effective therapies. Using a state-of-the-art combination of gene expression profiling and functional annotation of human tumor cells, and surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry of patient serum, we have shown that changes in tumor biochemistry correlate with disease progression and help to define the aggressive tumor phenotype. Based on these approaches, it is apparent that the metastatic phenotype of tumor cells is extremely complex. The identification of the phenotype of tumor cells has benefited greatly from the application of gene expression profiling (microarray analysis). This technology has been used by many investigators to identify changes in gene expression and cytokine and growth factor elaboration (such as interleukin 8). The tumor phenotype(s) presumably also include changes in the cell surface carbohydrate profile (via altered glycosyltransferase expression) and heparan sulfate expression (via increased heparanase activity), to name but a few. These specific alterations in gene expression, identified by functional annotation of accumulated microarray data, have been validated using a variety of approaches. Collectively, the data described here suggest that each of these activities is associated with distinct aspects of the aggressive tumor cell phenotype. Collectively, the data suggest that multiple factors constitute the complex phenotype of metastatic tumor cells. In particular, the differences observed in gene expression profiles and serum protein biomarkers play a critical role in defining the mechanisms responsible for bone-specific colonization and growth of tumors in bone. Future studies will identify the mechanisms that participate in the formation of secondary tumor growths of cancers in bone.

AB - Although the control of bone metastasis has been the focus of intensive investigation, relatively little is known about the molecular mechanisms that regulate or predict the process, even though widespread skeletal dissemination is an important step in the progression of many tumors. As a result, understanding the complex interactions contributing to the metastatic behavior of tumor cells is essential for the development of effective therapies. Using a state-of-the-art combination of gene expression profiling and functional annotation of human tumor cells, and surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry of patient serum, we have shown that changes in tumor biochemistry correlate with disease progression and help to define the aggressive tumor phenotype. Based on these approaches, it is apparent that the metastatic phenotype of tumor cells is extremely complex. The identification of the phenotype of tumor cells has benefited greatly from the application of gene expression profiling (microarray analysis). This technology has been used by many investigators to identify changes in gene expression and cytokine and growth factor elaboration (such as interleukin 8). The tumor phenotype(s) presumably also include changes in the cell surface carbohydrate profile (via altered glycosyltransferase expression) and heparan sulfate expression (via increased heparanase activity), to name but a few. These specific alterations in gene expression, identified by functional annotation of accumulated microarray data, have been validated using a variety of approaches. Collectively, the data described here suggest that each of these activities is associated with distinct aspects of the aggressive tumor cell phenotype. Collectively, the data suggest that multiple factors constitute the complex phenotype of metastatic tumor cells. In particular, the differences observed in gene expression profiles and serum protein biomarkers play a critical role in defining the mechanisms responsible for bone-specific colonization and growth of tumors in bone. Future studies will identify the mechanisms that participate in the formation of secondary tumor growths of cancers in bone.

UR - http://www.scopus.com/inward/record.url?scp=33750703626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750703626&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1070

DO - 10.1158/1078-0432.CCR-06-1070

M3 - Review article

C2 - 17062704

AN - SCOPUS:33750703626

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20 PART 2

ER -